Tag Archives: Threshold Pharmaceuticals

December, 2015

• 7 December

  Merck Drops Development of Cancer Drug After Studies Fail

  

  Darmstadt, Germany, December 7, 2015 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced that it is not planning to file for approval of evofosfamide in advanced soft tissue sarcoma and advanced pancreatic adenocarcinoma. The decision was made in light of results from two Phase III …

  Share

  • Facebook
  • Twitter
  • LinkedIn

May, 2015

• 12 May

  FDA Fast Tracks Merck KGaA’s Pancreatic Cancer Candidate

  

  The US Food and Drug Administration (FDA) has granted Fast Track designation to Merck KGaA and partner Threshold Pharmaceuticals’ investigational pancreatic cancer drug. The companies won Fast Track status for the development of evofosfamide, administered in combination with gemcitabine, for the treatment of previously untreated patients with metastatic or locally …

  Share

  • Facebook
  • Twitter
  • LinkedIn